Managment of Obesity in Diabetes mellitus - PowerPoint PPT Presentation

About This Presentation
Title:

Managment of Obesity in Diabetes mellitus

Description:

state of the art presentation 2015 – PowerPoint PPT presentation

Number of Views:273
Slides: 53
Provided by: Tarekareny69
Category:

less

Transcript and Presenter's Notes

Title: Managment of Obesity in Diabetes mellitus


1
Management of Obesity in DM Dealing with a Bad
Companion
  • By
  • Tarek Al Areeny , MD
  • tarekareny69_at_yahoo.com
  • www.elarenycenter.com
  • 01092933193

2
Presentation Outlines
  • Obesity definition stages
  • Diabetes Prediabetes diagnostic criteria
  • Diabetes obesity Comorbidity, and why they
    are considered Bad Companion?
  • Multidisciplinary approach to managing coexistent
    type 2 diabetes and obesity
  • lifestyle Modifications
  • Medications
  • Bariatric surgery its impact on type
    II DM
  • Take Home Messages

3
(No Transcript)
4
Obesity definition stages
  • Overweight and Obesity are defined as degrees of
    excess weight that are associated with increases
    in morbidity and mortality.
  • But weight alone is not an adequate measure of
    adiposity so the calculation of the body mass
    index (BMI), which is weight (kg) divided by the
    height (meters) squared, gives a reasonable
    approximation of adiposity and this is widely
    used in both clinical practice and research.

5
(No Transcript)
6
(No Transcript)
7
Diabetes mellitus diagnostic criteria
8
Criteria for testing for DM in asymptomatic
adults
9
Categories of increased risk for diabetes
(prediabetes)
10
(No Transcript)
11
(No Transcript)
12
Diabetes Obesity Co-morbidity
  • In Nurses Health Study , it was Found that the
    most important risk factor for developing type 2
    diabetes was BMI
  • The relative risk of diabetes was 38.8 in women
    with BMI of 35 kg/m2 or higher , and 20.1 for
    women with BMI between 30-34.9 kg/m2 when
    compared to women with BMI less than 23 kg/m2
  • In fact , the relative risk was not only
    increased in the obese but in the overweight
    groups as well

13
Diabetes Obesity Co-morbidity
  • Similar results were found in the third National
    Health and Nutrition Examination survey (
    NHANES), denoting that the prevalence of DM was
    dramatically increased with an increase in BMI.
  • The prevalence of DM was 2.5 times higher in
    overweight men and 3 times in overweight women
    when compared to normal weight group.

14
Diabetes Obesity Co-morbidity
  • This prevalence continued to increase and was 6
    times higher in men and 5.5 times higher in women
    with BMI between 35 and 39.9 km/m2
  • Unfortunately, not only obesity increase the
    prevalence of diabetes,
  • it also makes it more difficult to treat !
  • why?

15
Why obesity hinders diabetes control and increase
mortality ?
  • Increase insulin resistance glucose intolerance
  • Exacerbating other metabolic complications such
    as hypertension and dyslipidemia
  • Regarding mortality, compared with normal weight
    individuals with diabetes, the mortality rate is
    2.5-3.3 times higher in diabetics with body
    weights that are 20-30 above their ideal weight
    and 5.2-7.9 times higher in those with body
    weights 40 above ideal weight

16
Why obesity hinders diabetes control and increase
mortality ?
  • The proposed mechanism of this increased
    mortality in obese diabetics may be due to
    excess body fat, particularly abdominal fat,
    along with the presence of insulin resistance
    leads to a Pro-Atherogenic lipid profile with
    high triglyceride and apolipoprotein B
    concentrations, an increased proportion of small
    dense LDL particles, and a reduced concentration
    of HDL cholesterol.

17
Why obesity hinders diabetes control and increase
mortality ?
  • This Pro-Atherogeinc factor, along with a
    pro-thrombotic and a pro-inflammatory profile
    significantly worsens an individuals risk of
    cardiovascular disease and overall mortality.

18
American Association of Clinical Endocrinologists
andAmerican College of Endocrinology Clinical
Practice Guidelines for Developing a Diabetes
Mellitus Comprehensive Care Plan
Writing Committee Cochairpersons Yehuda
Handelsman MD, FACP, FACE, FNLA Zachary T.
Bloomgarden, MD, MACE George Grunberger, MD,
FACP, FACE Guillermo Umpierrez, MD, FACP,
FACE Robert S. Zimmerman, MD, FACE
ENDOCRINE PRACTICE Vol 21 No. 4 April 2015
19
Diagnosis of Obesity and Staging of for Management
Q13. How is obesity managed in patients with
diabetes?
  • Diagnose obesity according to body mass index
    (BMI)
  • Overweight BMI 25-29.9 kg/m2
  • Obese BMI 30 kg/m2
  • Consider waist circumference measurement for
    patients with BMI between 25 and 35 kg/m2
  • Larger waist circumference higher risk for
    metabolic disease
  • Men gt102 cm (40 in)
  • Women gt88 cm (35 in)
  • Evaluate patients for obesity-related
    complications to determine disease severity and
    appropriate management

19
BMI 23-24.9 may be considered obese in certain
ethnicities perform waist circumference and use
ethnicity-specific criteria in risk analysis.
20
Medical Complications of Obesity
Q13. How is obesity managed in patients with
diabetes?
Obesity
Cardiometabolic
Biomechanical
Other
Dismotility/disability GERD Lung
functiondefects Osteoarthritis Sleep
apnea Urinaryincontinence
Hypertension
Dyslipidemia
Androgen deficiency Cancer Gallbladder
disease Psychologicaldisorders
Prediabetic states
PCOS
NAFLD
Diabetes
Cardiovascular Disease
GERD, gastroesophageal reflux disease NAFLD,
nonalcoholic fatty liver disease PCOS,
polycystic ovary syndrome. Pi-Sunyer X. Postgrad
Med. 200912121-33.
21
(No Transcript)
22
Multidisciplinary approach to managing
coexistent type 2 diabetes and obesity (Diabesity)
  • Weight management is critical for limiting the
    development of glucose intolerance and
    progression from a state of impaired glucose
    tolerance to diabetes, as well as for optimal
    management in those who go on to develop T2D.
  • However, a number of current diabetes therapies
    promote weight gain in an already overweight
    population

23
Multidisciplinary approach to managing
coexistent type 2 diabetes and obesity (Diabesity)
  • This complexity means that an integrated and
    coordinated approach, using a dedicated
    multidisciplinary team focusing on managing both
    T2D and obesity in unified manner, is required.
  • The aim of the service is to manage the complex
    healthcare needs of people with diabesity and to
    address both conditions in a unified way,
    simultaneously optimizing glycemic control and
    weight management.

24
Value of this Multidisciplinary approach in
managing Diabesity
  • Most clinicians will agree that a
    multidisciplinary one-stop clinic approach
    improves patient adherence, thereby
    simultaneously optimizing glycaemic control and
    weight management. This leads to cost savings in
    terms of pharmacotherapy usage and healthcare
    professionals time.

25
Members of the multidisciplinary team (MDT) in
managing diabesity
  • A consultant , diabesity specialist nurse,
    clinical psychologist, specialist dietitian,
    physiotherapist, occupational therapist, moving
    and handling specialist, and a coordinator.
  • 8 members
  • With this combined expertise, the service is able
    to address all aspects of T2D and obesity in a
    way that optimizes the management of both
    conditions.

26
Referral to the service procedure
  • people are accepted into the diabesity service if
    they have T2D with an HbA1c level (gt8) and a BMI
    gt27.5 kg/m2.
  • Following referral, individuals undergo initial
    assessment by the consultant. These measure a
    range of biometric and psychological parameters,
    aimed at evaluating the individuals status with
    regard to their diabetes and obesity.

27
Initial investigations
  • A number of initial investigations are required
    to give a detailed understanding of the
    physiological health status of individuals
    referred to the service. Initial investigations
    requested include baseline kidney and liver
    function tests, full blood count and HbA1c level.
  • Endocrine abnormality is an established cause of
    weight gain in around 10 of people attending the
    diabesity clinic, and is assessed by using blood
    tests looking for thyroid dysfunction.

28
Initial investigations
  • If indicated, tests for hypogonadism and
    hypercortisolism are organized.
  • Sleep patterns and daytime sleepiness are also
    assessed using the Epworth Sleepiness Scale if
    the score is 10, patients are referred for sleep
    study to rule out obstructive sleep apnoea.
  • Patients are also asked to complete food, blood
    glucose and hunger pattern diaries and to bring
    them to each appointment.

29
Weight management at Diabesity Clinic
  • Weight loss is a 1st priority in a patient with
    newly diagnosed type 2 DM
  • Calorie restriction and Weight loss have a
    positive effect on almost every risk factor
    associated with diabetes and obesity

30
Weight management at Diabesity Clinic
  • Regarding Weight loss, There is a significant
    decrease in fasting glucose levels in those
    patients who experienced weight loss in the first
    3 months .
  • This was also accompanied by a decrease in
    fasting insulin levels, increase in insulin
    sensitivity and improvement of beta-cell function

31
Weight management at Diabesity Clinic
  • Similar improvements are also noted in coexisting
    conditions such as hypertension and dyslipidemia
  • In 1990 Mike Lean demonstrated that for people
    with type 2 DM, at 12 months from diagnosis, each
    1 kg of weight loss was associated with 3-4
    months increased survival.

32
Weight management at Diabesity Clinic
  • A 10 reduction in weight can result in a
  • 30-40 reduction in diabetes-related deaths
  • 15 reduction in HbA1c
  • 30-50 reduction in fasting glucose
  • 10 reduction in total cholesterol.
  • without doubt weight loss should be a goal
    standard outcome in type 2 diabetes

33
Artificial weight loss
  • Weight loss can be a sign of poorly controlled
    diabetes. Glycosuria can cause artificial
    weight loss if blood glucose levels are
    persistently above the renal threshold, ( usually
    180 mg/dl)
  • All medical therapies that correct hyperglycemia
    will cause indirect weight gain through reduced
    glycosuria and associated calorie loss.
  • This means that as medical therapies are
    commenced, small deficits in calorie intake
    should be negotiated to limit weight gain. For
    some individuals, weight maintenance might be a
    more realistic option

34
Prescribing a diet for diabesity patients
  • An overweight patient ( BMI 25-30 kg/m2) should
    be started on a reducing diet of approximately
    1000-1500 kcal daily.
  • Opinions vary as to whether obese individuals,
    BMI ?30 kg/m2, should be advised on even greater
    caloric restriction a target of 800-1000 kcal
    daily is ideal, although many patients will have
    difficulty complying with this.
  • While there are usually advantages to a slow and
    steady approach to weight loss, others advocate
    using a newly diagnosed patients high motivation
    to aim for more rapid loss.

35
Prescribing a diet for diabesity patients
  • For most people changing the dietary habits of a
    lifetime is challenging, so one needs to take a
    sympathetic approach.
  • A diet history should be taken, and review of a
    complete 3-day diet diary, including all snacks,
    can lead many patients to recognize previously
    unappreciated sources of excess calories ( i.e.
    soft drinks and fruit juices)
  • Foods that are labeled diabetic are not
    recommended, as they usually contain nonglucose
    refined sugars such as sucrose or fructose.

36
Prescribing a diet for diabesity patients
  • Artificial sweeteners are useful and could be
    used as an alternative to sugars concerns that
    they may cause cancer have not been confirmed.
  • Patients on insulin or on oral agents should be
    advised to eat the same amount at the same time
    each day
  • Tailor the diet of the patent according to the
    previous rules with carbohydrates constitutes
    about 55,meanwhile, fats and proteins,
    constitute 15 and 30 respectively

37
Exercise
  • Encourage small changes on overall lifestyle
    changes, for example
  • using stairs instead of elevators
  • Parking at the point furthest from ones
    place of destination
  • Getting off the bus a stop early
  • walking faster walking a dog
  • Regular scheduled exercise, even if only
    walking, should be encouraged, perhaps even
    prescribed, the aim being at least a half-hour
    each day on average

38
Pharmacologic obesity therapy
  • Pharmacologic obesity therapy is indicated with
    BMI 27 with comorbidity ( hypertension
    dyslipidemia - obstructive sleep apnea) or BMI ?
    30
  • If an individual has a history of unsuccessfully
    losing and maintain weight with lifestyle
    interventions, he/she is a candidate for obesity
    pharmacotherapy
  • Combined lifestyle changes weight loss
    medications can produce greater weight loss and
    cardiometabolic improvements compared with
    lifestyle alone

39
Weight loss medications available in USA
  • Phentermine
  • Phentermine/topiramte
  • Diethylepropion
  • Lorcaserine
  • Orlistat
  • Naltrexone/bupropion
  • Liraglutide

40
Matching weight loss medications to patient
profiles
  • Phentermine Diethylepropion are associated with
    blood pressure elevations , so both are not
    recommended for patients with uncontrolled
    hypertension, a history of cardiovascular disease
    or arrhythmias, or seizures
  • Lorcaserine is not recommended in patients with
    depression and treated with SSRI Or SNRI , for
    fear of development of serotonin syndrome
  • Orlistat, a lipase inhibitor, is likely safe for
    all individuals

41
Anti hyperglycemic medications choice in type 2
DM
  • Anti hyperglycemic medications that promote
    weight loss or weight neutrality are recommended
  • GLP-1 receptor agonists namely liraglutide
    which is the only one approved by FDA for weight
    loss
  • SGLT2 inhibitors , Metformin, DPP-4
    inhibitors pramlintide ( all are not FDA
    approved for weight loss )

42
Individuals with type 2 DM who require insulin
  • Add metformin, pramlintide, or a GLP-1 receptor
    agonist to mitigate insulin associated weight
    gain
  • First-line insulin basal is preferable (
    consider prior to premixed or combination insulin
    therapy)

43
Role of bariatric surgery
  • bariatric surgery should be considered as the
    final step in weight management strategy, also in
    combination with appropriate lifestyle
    modifications
  • Recent guidelines recognize the benefits of
    bariatric procedures in carefully selected type 2
    diabetic patients with BMI 35 kg/m2
  • Furthermore, surgical weight loss interventions
    can be considered as an alternative treatment for
    poorly controlled type 2 diabetes patients with
    mild to moderate obesity (BMI 30-35 kg/m2)

44
Main types of bariatric surgeries
45
Main types of bariatric surgeries
46
Gastric Banding
http//www.healthierweight.co.uk/obesity-surgery/g
astric-band/what-is-a-gastric-band/how-does-the-ba
nd-work/
47
(No Transcript)
48
(No Transcript)
49
http//www.webmd.com/diet/video/bariatric-surgery
50
Take home messages
  • Diabesity is a growing worldwide epidemic that
    must be taken seriously
  • Presence of obesity in a diabetic patient could
    hinder both diabetes control obesity management
  • Multidisciplinary approach is considered nowadays
    the most successful way of management of both
    conditions

51
Take home messages
  • weight reduction through dietary interventions,
    exercise pharcotherapy must be a 1st and long
    lasting step in management of diabesity cases
  • Lastly, bariatric surgeries may be indicated in
    some categories of patients according to their
    special situations

52
(No Transcript)
Write a Comment
User Comments (0)
About PowerShow.com